Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Muse approvable for treatment of impotence

Oct. 11, 1996

Aldose reductase inhibitor in phase III at Fujisawa

Oct. 11, 1996

Antidiabetic agents from Yamanouchi's clinical pipeline

Oct. 11, 1996

New approval for Lilly's Humalog

Oct. 11, 1996

UCSF scientists discover protein involved in insulin resistance

Oct. 11, 1996

Novel, highly potent antihyperglycemic agents from SmithKline Beecham

Oct. 11, 1996

Nissan Chem. claims hypoglycemic agents for diabetes

Oct. 11, 1996

Progress in development of NPS's R-568

Oct. 11, 1996

Future metabolic agents in the Yamanouchi pipeline

Oct. 11, 1996

ProScript and Roche to develop compounds for cachexia

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...